IL211366A0 - Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers - Google Patents
Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancersInfo
- Publication number
- IL211366A0 IL211366A0 IL211366A IL21136611A IL211366A0 IL 211366 A0 IL211366 A0 IL 211366A0 IL 211366 A IL211366 A IL 211366A IL 21136611 A IL21136611 A IL 21136611A IL 211366 A0 IL211366 A0 IL 211366A0
- Authority
- IL
- Israel
- Prior art keywords
- cancers
- malignant melanoma
- cancer drugs
- metastatic malignant
- uses relating
- Prior art date
Links
- 206010027480 Metastatic malignant melanoma Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 208000021039 metastatic melanoma Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2230CH2008 | 2008-09-15 | ||
| PCT/IN2009/000504 WO2010029577A2 (en) | 2008-09-15 | 2009-09-14 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL211366A0 true IL211366A0 (en) | 2011-04-28 |
Family
ID=41565903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL211366A IL211366A0 (en) | 2008-09-15 | 2011-02-23 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8258119B2 (enExample) |
| EP (1) | EP2324006B1 (enExample) |
| JP (1) | JP2012502900A (enExample) |
| KR (1) | KR20110063537A (enExample) |
| CN (1) | CN102149703B (enExample) |
| AU (1) | AU2009290365B2 (enExample) |
| BR (1) | BRPI0913485A2 (enExample) |
| CA (1) | CA2736732A1 (enExample) |
| IL (1) | IL211366A0 (enExample) |
| NZ (1) | NZ591394A (enExample) |
| WO (1) | WO2010029577A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1006651A2 (pt) * | 2009-04-27 | 2015-08-25 | Kasina Laila Innova Pharmaceuticals Private Ltd | Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres |
| NO2686520T3 (enExample) | 2011-06-06 | 2018-03-17 | ||
| CN103717214A (zh) * | 2011-06-06 | 2014-04-09 | 阿克比治疗有限公司 | 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物 |
| HUE066123T2 (hu) | 2013-06-13 | 2024-07-28 | Akebia Therapeutics Inc | Készítmények és módszerek anémia kezelésére |
| US9593095B2 (en) | 2013-06-14 | 2017-03-14 | Duke University | Methods for the treatment of bacterial infections |
| DE112014006766T5 (de) * | 2014-06-27 | 2017-04-27 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Herstellung und medizinische Verwendung von Triazenen |
| CA2974691A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| NZ735973A (en) | 2015-04-01 | 2023-06-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| KR20180008594A (ko) | 2015-05-18 | 2018-01-24 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 및 그의 용도 |
| JP6768716B2 (ja) | 2015-06-19 | 2020-10-14 | シン−ナット プロダクツ エンタープライズ エルエルシー | カルボプラチンベースの共結晶の医薬組成物及びその用途 |
| EP3297440A4 (en) * | 2015-06-19 | 2019-04-10 | Syn-Nat Products Enterprise LLC | COMPOSITION WITH CARBOPLATIN AND USE |
| KR20180021805A (ko) | 2015-06-25 | 2018-03-05 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 약제학적 공-결정 조성물 및 이의 용도 |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US12612367B2 (en) | 2019-12-10 | 2026-04-28 | Akebia Therapeutics, Inc. | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| KR102648781B1 (ko) | 2021-11-09 | 2024-03-19 | 국립공주대학교 산학협력단 | 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1020641B (de) | 1955-10-15 | 1957-12-12 | Basf Ag | Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure |
| CA968347A (en) * | 1968-09-09 | 1975-05-27 | John F. Gerster | Substituted pyrazoles and process |
-
2009
- 2009-09-14 BR BRPI0913485A patent/BRPI0913485A2/pt not_active IP Right Cessation
- 2009-09-14 WO PCT/IN2009/000504 patent/WO2010029577A2/en not_active Ceased
- 2009-09-14 NZ NZ591394A patent/NZ591394A/xx not_active IP Right Cessation
- 2009-09-14 EP EP09760623.0A patent/EP2324006B1/en not_active Not-in-force
- 2009-09-14 AU AU2009290365A patent/AU2009290365B2/en not_active Ceased
- 2009-09-14 KR KR1020117008490A patent/KR20110063537A/ko not_active Ceased
- 2009-09-14 CN CN200980135652.3A patent/CN102149703B/zh not_active Expired - Fee Related
- 2009-09-14 CA CA2736732A patent/CA2736732A1/en not_active Abandoned
- 2009-09-14 JP JP2011526634A patent/JP2012502900A/ja active Pending
- 2009-09-15 US US12/559,811 patent/US8258119B2/en not_active Expired - Fee Related
-
2011
- 2011-02-23 IL IL211366A patent/IL211366A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100068178A1 (en) | 2010-03-18 |
| CN102149703A (zh) | 2011-08-10 |
| JP2012502900A (ja) | 2012-02-02 |
| CA2736732A1 (en) | 2010-03-18 |
| KR20110063537A (ko) | 2011-06-10 |
| CN102149703B (zh) | 2014-09-10 |
| EP2324006B1 (en) | 2014-08-13 |
| WO2010029577A2 (en) | 2010-03-18 |
| WO2010029577A3 (en) | 2010-05-06 |
| BRPI0913485A2 (pt) | 2016-06-07 |
| AU2009290365B2 (en) | 2014-08-14 |
| US8258119B2 (en) | 2012-09-04 |
| EP2324006A2 (en) | 2011-05-25 |
| NZ591394A (en) | 2013-03-28 |
| AU2009290365A1 (en) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215789A0 (en) | Anti-cancer drugs, and uses relating for malignant malignant melanoma and other cancers | |
| BRPI0913485A2 (pt) | medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres. | |
| EP2108630A4 (en) | FRITTE DIAMOND | |
| EP2168059A4 (en) | INTEGRATED SHARING OF ELECTRONIC DOCUMENTS | |
| DK2331118T5 (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers | |
| IL214167A0 (en) | New adenosine receptor ligands and uses thereof | |
| EP2140692A4 (en) | BETTER ZONE DETERMINATION | |
| IL190382A0 (en) | Detecting prostate cancer | |
| ZA201004495B (en) | Rotary machine scroll structure and rotary machine | |
| EP2520651A4 (en) | SIRNA FOR INHIBITING THE C-MET EXPRESSION AND ANTICREPLAY COMPOSITION THEREWITH | |
| EP2113496A4 (en) | DIAMOND SINTER BODY | |
| EP2268146A4 (en) | ANTICANCER AGENTS BASED ON INDOLINE | |
| AP2009004952A0 (en) | Pharmaceutical carrier composition and pharmaceutical composition | |
| EP2139908A4 (en) | REMOVAL OF PROTEIN Li INVOLVED IN Li-RNAi CONSTRUCTIONS IN ANTICANCER IMMUNOTHERAPY | |
| IL214319A (en) | Chemotherapeutic agent for cancer containing cholesterol derivative and anticancer agent | |
| GB0714483D0 (en) | Improvements in the chemotherapy of cancer | |
| GB0809730D0 (en) | Improvements in the chemotherapy of cancer | |
| GB0818566D0 (en) | Improvements in the chemotherapy of cancer | |
| GB0722641D0 (en) | Prevention of metastatic cancer | |
| GB0718208D0 (en) | Improvement in cancer chemotherapy | |
| GB0822018D0 (en) | Prevention of metastatic cancer | |
| GB2440643B (en) | Antitumor combinations comprising taxane derivatives | |
| GB0811599D0 (en) | Improvements in anticancer drugs | |
| GB0814307D0 (en) | Compacts comprising boron carbide and an ultrahard phase | |
| GB0808939D0 (en) | Compacts comprising boron carbide and an ultrahard phase |